参考文献/References:
[1] Zhang C,Chen Z,Mo C,et al. Real-world cardiovascular toxicity of immune checkpoint inhibitors in cancer patients:a retrospective controlled cohort study[J]. Am J Cancer Res,2021,11(12):6074-6085.
[2] Li C,Bhatti SA,Ying J. Immune checkpoint inhibitors-associated cardiotoxicity[J]. Cancers (Basel),2022,14(5):1145.
[3] Rubio-Infante N,Ramírez-Flores YA,Castillo EC,et al. Cardiotoxicity associated with immune checkpoint inhibitor therapy:a meta-analysis[J]. Eur J Heart Fail,2021,23(10):1739-1747.
[4] Mahmood SS,Fradley MG,Cohen JV,et al. Myocarditis in patients treated with immune checkpoint inhibitors[J]. J Am Coll Cardiol,2018,71(16):1755-1764.
[5] Dolladille C,Ederhy S,Allouche S,et al. Late cardiac adverse events in patients with cancer treated with immune checkpoint inhibitors[J]. J Immunother Cancer,2020,8(1):e000261.
[6] Awadalla M,Golden DLA,Mahmood SS,et al. Influenza vaccination and myocarditis among patients receiving immune checkpoint inhibitors[J]. J Immunother Cancer,2019,7(1):53.
[7] Hu J,Tian R,Ma Y,et al. Risk of cardiac adverse events in patients treated with immune checkpoint inhibitor regimens:a systematic review and meta-analysis[J]. Front Oncol,2021,11:645245.
[8] Chitturi KR,Xu J,Araujo-Gutierrez R,et al. Immune checkpoint inhibitor-related adverse cardiovascular events in patients with lung cancer[J]. JACC CardioOncol,2019,1(2):182-192.
[9] Stein-Merlob AF,Rothberg MV,Ribas A,et al. Cardiotoxicities of novel cancer immunotherapies [J]. Heart,2021,107(21):1694-1703.
[10] Schneider BJ ,Naidoo J,Santomasso BD,et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy:ASCO guideline update[J]. J Clin Oncol,2021,39(36):4073-4126.
[11]Caforio AL,Pankuweit S,Arbustini E,et al. Current state of knowledge on aetiology,diagnosis,management,and therapy of myocarditis:a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases[J]. Eur Heart J,2013,34(33):2636-2648,2648a-2648d.
[12]L?ubli H,Balmelli C,Bossard M,et al. Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma[J]. J Immunother Cancer,2015,3:11.
[13]Tadokoro T,Keshino E,Makiyama A,et al. Acute lymphocytic myocarditis with anti-PD-1 antibody nivolumab[J]. Circ Heart Fail,2016,9(10):e003514.
[14] Kumar K,Przybylowicz R,Nazer B,et al. Sinus arrest and cardiogenic shock precipitated by immune checkpoint inhibitors[J]. JACC CardioOncol,2020,2(5):810-814.
[15]Escudier M,Cautela J,Malissen N,et al. Clinical features,management,and outcomes of immune checkpoint inhibitor-related cardiotoxicity[J]. Circulation,2017,136(21):2085-2087.
[16]Awadalla M,Mahmood SS,Groarke JD,et al. Global longitudinal strain and cardiac events in patients with immune checkpoint inhibitor-related myocarditis[J]. J Am Coll Cardiol,2020,75(5):467-478.
[17]Naganuma K,Horita Y,Matsuo K,et al. An autopsy case of late-onset fulminant myocarditis induced by nivolumab in gastric cancer[J]. Intern Med,2022,DOI:10.2169/internalmedicine.9161-21.Online ahead of print.
[18]Guo CW,Alexander M,Dib Y,et al. A closer look at immune-mediated myocarditis in the era of combined checkpoint blockade and targeted therapies[J]. Eur J Cancer,2020,124:15-24.
[19]Pohl J,Mincu RI,Mrotzek SM,et al. ECG changes in melanoma patients undergoing cancer therapy—Data from the ECoR registry[J]. J Clin Med,2020,9(7):2060.
[20]Zlotoff DA,Hassan MZO,Zafar A,et al. Electrocardiographic features of immune checkpoint inhibitor associated myocarditis[J]. J Immunother Cancer,2021,9(3):e002007.
[21]Gr?ni C,Eichhorn C,Bière L,et al. Prognostic value of cardiac magnetic resonance tissue characterization in risk?stratifying patients with suspected?myocarditis[J]. J Am Coll Cardiol,2017,70(16):1964-1976.
[22]Yang F,Wang J,Li W,et al. The prognostic value of late gadolinium enhancement in myocarditis and clinically suspected myocarditis:systematic review and meta-analysis[J]. Eur Radiol,2020,30(5):2616-2626.
[23] Ferreira VM,Schulz-Menger J,Holmvang G,et al. Cardiovascular magnetic resonance in nonischemic?myocardial inflammation:expert recommendations[J]. J Am Coll Cardiol,2018,72(24):3158-3176.
[24] Higgins AY,Arbune A,Soufer A,et al. Left ventricular myocardial strain and tissue characterization by cardiac magnetic resonance imaging in immune checkpoint inhibitor associated cardiotoxicity[J]. PLoS One,2021,16(2):e0246764.
[25]Thavendiranathan P,Zhang L,Zafar A,et al. Myocardial T1 and T2 mapping by magnetic resonance in patients?with?immune checkpoint inhibitor-associated myocarditis[J]. J Am Coll Cardiol,2021,77(12):1503-1516.
[26]Wintersperger BJ,Calvillo-Argüelles O,Lheureux S,et al. Immune checkpoint inhibitor-related myocarditis:an illustrative case series of applying the updated Cardiovascular Magnetic Resonance Lake Louise Criteria[J]. Eur Heart J Case Rep,2022,6(1):ytab478.
[27]Zhang L,Awadalla M,Mahmood SS,et al. Cardiovascular magnetic resonance in immune checkpoint inhibitor-associated myocarditis[J]. Eur Heart J,2020,41(18):1733-1743.
[28]Mirabel M,Callon D,Bruneval P,et al. Late-onset giant cell myocarditis due to enterovirus during treatment with immune checkpoint inhibitors[J]. JACC CardioOncol,2020,2(3):511-514.
[29]Lehmann LH,Cautela J,Palaskas N,et al. Clinical strategy for the diagnosis and treatment of immune checkpoint inhibitor-associated myocarditis:a narrative review[J]. JAMA Cardiol,2021,6(11):1329-1337.
[30]Thygesen K,Mair J,Giannitsis E,et al. How to use high-sensitivity cardiac troponins in acute cardiac care[J]. Eur Heart J,2012,33(18):2252-2257.
[31]Lee CC,Huang SS,Yeo YH,et al. High-sensitivity-cardiac troponin for accelerated diagnosis of acute myocardial infarction:a systematic review and meta-analysis[J]. Am J Emerg Med,2020,38(7):1402-1407.
[32]Wang XY,Zhang F,Zhang C,et al. The biomarkers for acute myocardial infarction and heart failure[J]. Biomed Res Int,2020,2020:2018035.
[33]Lyon AR,Yousaf N,Battisti NML,et al. Immune checkpoint inhibitors and cardiovascular toxicity[J]. Lancet Oncol,2018,19(9):e447-e458.
[34]Rhee JY,Torun N,Neilan TG,et al. Consider myocarditis when patients treated with immune checkpoint inhibitors present with ocular symptoms[J]. Oncologist,2022,27(5):e402-e405.
[35]Baranseh J,Ouryvaev A,Moady G,et al. Pro-BNP in the differential diagnosis of dyspnea in patients treated with immune-checkpoint inhibitors:case report [J]. J Oncol Pharm Pract,2022:10781552221074007.
[36]Yuan M,Zang L,Xu A,et al. Dynamic changes of serum heart type-fatty acid binding protein in cancer patients treated with immune checkpoint inhibitors[J]. Front Pharmacol,2021,12:748677.
[37]Zhang L,Zlotoff DA ,Awadalla M,et al. Major adverse cardiovascular events and the timing and dose of corticosteroids in immune checkpoint inhibitor-associated myocarditis[J]. Circulation,2020,141(24):2031-2034.
[38]Bonaca MP,Olenchock BA,Salem JE,et al. Myocarditis in the setting of cancer therapeutics:proposed case definitions for emerging clinical syndromes in cardio-oncology[J]. Circulation,2019,140(2):80-91.
相似文献/References:
[1]孙文静,孙林,赵新湘.心脏核磁共振在急性心肌炎中的研究进展[J].心血管病学进展,2015,(5):622.[doi:10.3969/j.issn.1004-3934.2015.05.026]
SUN Wenjing,SUN Lin,ZHAO Xinxiang.Evolution of Cardiac Magnetic Resonance Imaging in Acute Myocarditis[J].Advances in Cardiovascular Diseases,2015,(10):622.[doi:10.3969/j.issn.1004-3934.2015.05.026]
[2]陈文浩 张焕基 郭攸胜 张东辉.活检证实病毒性心肌炎的治疗策略及预后[J].心血管病学进展,2019,(5):813.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.037]
Chen WenhaoZhang HuanjiGuo YoushengZhang Donghui.Treatment Strategy and Prognosis of Viral Myocarditis Confirmed by Biopsy[J].Advances in Cardiovascular Diseases,2019,(10):813.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.037]
[3]陈丰 苏强 朱继金.高迁移率族蛋白B1在心脏炎症反应性疾病中的研究进展[J].心血管病学进展,2019,(8):1111.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.010]
CHEN Feng,SU Qiang,ZHU Jijin.Research Progress of HMGB1 in Myocardial Inflammatory Reactivity Disease[J].Advances in Cardiovascular Diseases,2019,(10):1111.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.010]
[4]张艺文 蔡琳 秦莉 杨晓倩 汪汉.基于网络药理学的参麦注射液治疗新型冠状病毒感染合并心肌炎的机制研究[J].心血管病学进展,2020,(10):1101.[doi:10.16806/j.cnki.issn.1004-3934.2020.10.024]
ZHANG YiwenCAI LinQIN LiYANG XiaoqianWANG Han.Shenmai Injection for COVID-19 with Myocarditis Based on Network Pharmacology[J].Advances in Cardiovascular Diseases,2020,(10):1101.[doi:10.16806/j.cnki.issn.1004-3934.2020.10.024]
[5]王斯 魏欣 肖乾凤 陈晓平.心肌炎的分类及治疗进展[J].心血管病学进展,2021,(4):337.[doi:10.16806/j.cnki.issn.1004-3934.2021.04.012]
WANG Si,WEI Xin,XIAO Qianfeng,et al.The Classification and Treatment Progress of Myocarditis[J].Advances in Cardiovascular Diseases,2021,(10):337.[doi:10.16806/j.cnki.issn.1004-3934.2021.04.012]
[6]杨晓倩 秦莉 张艺文 汪汉.苦参治疗新型冠状病毒感染合并心肌炎的网络药理学分析[J].心血管病学进展,2021,(6):566.[doi:10.16806/j.cnki.issn.1004-3934.2020.12.021]
YANG Xiaoqian,QIN Li,ZHANG Yiwen,et al.Network Pharmacological Analysis of Sophora Flavescens on Novel Coronavirus Infection complicated with Myocarditis[J].Advances in Cardiovascular Diseases,2021,(10):566.[doi:10.16806/j.cnki.issn.1004-3934.2020.12.021]
[7]孙睿 王阿曼.肿瘤免疫治疗相关动脉粥样硬化的研究进展[J].心血管病学进展,2023,(7):585.[doi:10.16806/j.cnki.issn.1004-3934.2023.07.003]
SUN Rui,WANG Aman.Atherosclerosis Associated with Cancer Immune Therapy[J].Advances in Cardiovascular Diseases,2023,(10):585.[doi:10.16806/j.cnki.issn.1004-3934.2023.07.003]
[8]邓悦 周晓阳.免疫检查点抑制剂相关心脏毒性的临床特点及研究进展[J].心血管病学进展,2023,(10):905.[doi:10.16806/j.cnki.issn.1004-3934.2023.10.010]
DENG YueZHOU Xiaoyang?/html>.Clinical Characteristics and Progress of?ardiac Toxicity Associated with Immune Checkpoint Inhibitors[J].Advances in Cardiovascular Diseases,2023,(10):905.[doi:10.16806/j.cnki.issn.1004-3934.2023.10.010]
[9]陆睿 廖祎 王敏 林心情 鲁明军.免疫检查点抑制剂相关动脉粥样硬化性心血管疾病研究进展[J].心血管病学进展,2024,(2):141.[doi:10.16806/j.cnki.issn.1004-3934.2024.02.010]
LU Rui,LIAO Yi,WANG Min,et al.Research Progress on Mechanism and Clinical Significance of Immune Checkpoint Inhibitor Related Arteriosclerotic Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2024,(10):141.[doi:10.16806/j.cnki.issn.1004-3934.2024.02.010]
[10]朱煜欣 王天博 刘晓翰 张悦 何韵 黄刚 徐俊波.炎症性心肌病的机制及治疗进展[J].心血管病学进展,2024,(4):317.[doi:10.16806/j.cnki.issn.1004-3934.2024.04.007]
ZHU Yuxin,WANG Tianbo,LIU Xiaohan,et al.Advances in the Pathogenesis and Treatment of Inflammatory Cardiomyopathy[J].Advances in Cardiovascular Diseases,2024,(10):317.[doi:10.16806/j.cnki.issn.1004-3934.2024.04.007]
[11]肖乾凤 王斯 刘燕扬 魏欣.免疫检查点抑制剂相关性心肌炎的诊治[J].心血管病学进展,2022,(7):610.[doi:10.16806/j.cnki.issn.1004-3934.2022.07.000]
Inhibitors-Related Myocarditis.Diagnosis and Treatment of Immune Checkpoint[J].Advances in Cardiovascular Diseases,2022,(10):610.[doi:10.16806/j.cnki.issn.1004-3934.2022.07.000]